Protalix BioTherapeutics, Inc. has completed a private stock placement
Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.
Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.
Talk to the deal team
PrincipalTel Aviv, Israel
PartnerTel Aviv, Israel
SupportTel Aviv, Israel
CAPZA and RAISE Impact have invested in Oui Care to accelerate its internal and external growth strategies
The shareholders and management of Oui Care have raised funds and restructured its debt for up to US$78.5 million (US$42.2 million for external growth and US$36.3 million in refinancing). This investment will support Oui Care and its management in this new stage of development.Learn more
Kardan Real Estate has issued bonds
Kardan Real Estate Ltd. has completed a fundraising to develop the business.Learn more
Ace Pharmaceuticals has been acquired by Gilde Buy Out Partners, Gilde Healthcare and Quadrum Capital
Ace Pharmaceuticals BV has been acquired by Gilde Buy Out Partners, Gilde Healthcare, Quadrum Capital and the management team.Learn more